Mild cognitive impairment (MCI) is a syndrome which, depending on various
neurobiological, psychological and social factors, carries a high risk of developing into …

A cascade of pathophysiological events is triggered in Alzheimer disease (AD) that
ultimately involves common cellular signaling pathways and leads to cellular and network …

Objective: To review the different pharmacological approaches to the cognitive, functional,
and behavioural manifestations of Alzheimer disease (AD). Methods: We searched and …

Experimental pharmacotherapy of cognitive impairment in Alzheimer's disease has seen a
recent proliferation of drug trials involving a wide variety of drugs. Many of the earlier studies …

Background Successful development of agents that improve cognition and behavior in
Alzheimer's disease (AD) is critical to improving the lives of patients manifesting the …

Methods A systematic review and meta-analysis was conducted including double-blind,
randomized, placebo-controlled trials. Outcomes were the improvement of apathy scales …

Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and
has become an urgent public health problem in most areas of the world. Substantial …

The major components of the cholinergic receptor system of the human brain include
projections from the basal forebrain nuclei, and utilize the two types of receptors that they …

Antagonism of the 5-HT 6 receptor is a promising approach for the symptomatic treatment of
Alzheimer's disease (AD). There is compelling preclinical evidence for the procognitive …

Rationale Previous studies have demonstrated reductions of serotonin 5-HT 2A receptors in
the neocortex of Alzheimer's disease (AD) patients. However, it is unclear whether such …